Mobile website
Archive > Volume 24 Issue 3 > 2017,24(3):259-263. DOI:10.3872/j.issn.1007-385X.2017.03.008 Prev Next
Clinical Research
Efficacy and safety of Imatinib in the 78 patients with advanced melanoma harboring KIT mutation
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective:To explore efficacy and safety of tyrosine kinase inhibitor, imatinib, in the patients with advanced melanoma haboring KIT mutation / amplification. Methods: Clinical data of 78 patients with advanced melanoma haboring KIT mutation/amplification who were hospitalized in the Department of Renal Cancer and Melanoma, Cancer Hospital of Peking University during November 2009 to September 2015 were retrospectively analyzed. All of the patients received an imatinib oral treatment (400 mg/d) until disease progression or occur of intolerable adverse reactions. Results: Curative effects of the 78 patients were evaluated. In the patients of the whole group, objective remission rate was 22.4% and disease control rate was 60.6%. Among the 17 patients who were partial remission, the 11 patients were 11 exon or 13 exon mutation. For the patients of whole group, median progression free time was 3.9 months (95% CI: 2.1~5.8 months), median overall survival time was 13.2 months (95% CI: 10.1~16.3 months), survival rate for 1 year was 57%, survival rate for 2 years was 36% and survival rate for 3 years was 19%. The most common adverse reactions included edema, fatigue, anorexia, rash and neutropenia (all incidence rate ≥10%), and no fatal drug-related adverse reactions were observed. Conclusion:Imatinib could have certain curative effect for treatment of the patients with advanced melanoma baboring KIT mutation / amplification, and good safety.
Keywords:
Project Supported:
Project supported by the National Natural Science Foundation of China (No.81172196, No.81102068, No.81272991, No.81301984), the Beijing Nova Program (No.XX2013027), Program for New Century Excellent Talents in University (No.NCET-13-0007), and the Beijing Talents Fund (No.2014000021223ZK26)
Clc Number:
